Oral zinc may lessen common cold symptoms but adverse effects are common

May 7, 2012

Oral zinc treatments may shorten the duration of symptoms of the common cold in adults, although adverse effects are common, according to a study published in CMAJ (Canadian Medical Association Journal).

Canadian researchers looked at 17 with 2121 participants between 1 and 65 years of age to determine the efficacy and safety of zinc in treating the common cold. All trials were double-blinded and used placebos as well as oral zinc preparations. The authors found that, compared with placebos, zinc significantly reduced the duration of cold symptoms, although the quality of evidence was moderate. High doses of ionic zinc were more effective than lower doses at shortening the duration of cold symptoms.

"We found that orally administered zinc shortened the duration of ," writes Dr. Michelle Science, The Hospital for (SickKids), Toronto, with coauthors at McMaster University. "These findings, however, are tempered by significant and quality of evidence."

There was weak evidence that people taking zinc were less likely to have symptoms after one week, although there was no difference in symptoms between the two groups at three days. While zinc appeared to reduce the duration of symptoms in adults, there was no apparent effect in children. Participants taking zinc treatment were more likely to experience adverse effects including bad taste and nausea.

Previous studies have shown conflicting effects of zinc in reducing cold symptom severity and the duration of symptoms.

"Until further evidence becomes available, there is only a weak rationale for physicians to recommend zinc for the treatment of the common cold," conclude the authors. "The questionable benefits must be balanced against the potential adverse effects."

Explore further: Zinc lozenges may shorten common-cold duration

More information: www.cmaj.ca/lookup/doi/10.1503/cmaj.111990

Related Stories

Zinc lozenges may shorten common-cold duration

July 26, 2011
Depending on the total dosage of zinc and the composition of lozenges, zinc lozenges may shorten the duration of common cold episodes by up to 40%, according to a study published in the Open Respiratory Medicine Journal.

Zinc lozenges may shorten common cold duration

August 16, 2011
Depending on the total dosage of zinc and the composition of lozenges, zinc lozenges may shorten the duration of common cold episodes by up to 40%, says Dr. Harri Hemila from the University of Helsinki.

Zinc supplementation does not protect young African children against malaria

November 22, 2011
A study led by Hans Verhoef, a researcher at Wageningen University, the Netherlands, and the London School of Hygiene and Tropical Medicine, UK, and published in this week's PLoS Medicine shows that supplementing young Tanzanian ...

Recommended for you

Cancer drugs' high prices not justified by cost of development, study contends

September 12, 2017
(HealthDay)— Excusing the sky-high price tags of many new cancer treatments, pharmaceutical companies often blame high research and development (R&D) costs.

Non-psychotropic cannabinoids show promise for pain relief

September 4, 2017
Some cancers love bone. They thrive in its nutrient-rich environment while gnawing away at the very substrate that sustains them, all the while releasing inflammatory substances that cause pain—pain so severe that opioids ...

Fentanyl drives rise in opioid-linked deaths in U.S.

August 31, 2017
(HealthDay)—Fentanyl, a synthetic narcotic, is a key player in America's continuing epidemic of opioid-related overdose deaths, two new studies report.

Eating triggers endorphin release in the brain

August 28, 2017
Finnish researchers have revealed how eating stimulates brain's endogenous opioid system to signal pleasure and satiety.

Cholesterol-lowering drugs may fight infectious disease

August 21, 2017
That statin you've been taking to lower your risk of heart attack or stroke may one day pull double duty, providing protection against a whole host of infectious diseases, including typhoid fever, chlamydia, and malaria.

Data revealed under FOI shows benefits of multiple sclerosis drug currently blocked by regulators

August 17, 2017
A drug that is blocked by the EU regulatory system has now been found to improve the quality of life of people with multiple sclerosis (MS), according to a study by Queen Mary University of London (QMUL).

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.